Charmacy Pharmaceutical Co Ltd
HKEX:2289
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CN |
C
|
Charmacy Pharmaceutical Co Ltd
HKEX:2289
|
1.5B HKD | -9.2 | |
US |
Mckesson Corp
NYSE:MCK
|
72.5B USD | 16.9 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 17.1 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 10.9 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.6B USD | 9.3 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 14 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -320.2 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 3.6 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.5B EUR | 18.3 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 15.6 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 21.9 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.